REFERENCES

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010 Dec 15;127(12):2893-917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90.
3. Wiangnon S, Veerakul G, Nuchprayoon I, Seksarn P, Hongeng S, Krutvecho T, et al. Childhood cancer incidence and survival 2003-2005, Thailand: study from the thai pediatric oncology group. Asian Pac J Cancer Prev. 2011;12(9):2215-20.
4. Attasara P, Buasom R. Hospital-based cancer registry 2010. Bangkok: National Cancer Institute, Division IT;2011.
5. Kamnerdsupaphon P, Srisukho S, Sumitsawan Y, Lorvidhaya V, Sukthomya V. Cancers in northern Thailand. Biomed Imaging Interv J. 2008 Jul;4(3):e46.
6. Sumitsawan Y, Srisukho S, Sastraruji A, Chaisaengkhum U, Maneesai P, Waisri N. Cancer survival in Chiang Mai, Thailand, 1993-1997. IARC Sci Publ. 2011(162):199-209.
7. Loeb LA, Ernster VL, Warner KE, Abbotts J, Laszlo J. Smoking and lung cancer: an overview. Cancer Res. 1984 Dec;44(12 Pt 1):5940-58.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.
9. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210.
10. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438.
11. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol. 1998 Jun;11(6):559-603.

12. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733-44.
13. Smith CJ, Perfetti TA, Rumple MA, Rodgman A, Doolittle DJ. "IARC Group 2B carcinogens" reported in cigarette mainstream smoke. Food Chem Toxicol. 2001 Feb;39(2):183-205.
14. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol. 2006 Oct;29(4):745-52.
15. Maser E. Significance of reductases in the detoxification of the tobacco-specific carcinogen NNK. Trends Pharmacol Sci. 2004 May;25(5):235-7.
16. Isin EM, Guengerich FP. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):314-29.
17. Jalas JR, Ding X, Murphy SE. Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab Dispos. 2003 Oct;31(10): 1199-202.
18. Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab Rev. 2002 Aug;34(3):667-76.
19. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996 Nov;24(11):1212-7.
20. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. Feb 1;120(2):521-32.
21. Khuhaprema T, Srivatanakul P. Colon and rectum cancer in Thailand: an overview. Jpn J Clin Oncol. 2008 Apr;38(4):237-43.
22. Ryan-Harshman M, Aldoori W. Diet and colorectal cancer: Review of the evidence. Can Fam Physician. 2007 Nov;53(11):1913-20.

23. Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. Genes, diet and inflammatory bowel disease. Mutat Res. 2007 Sep 1;622(1-2):70-83.
24. Gonzalez CA. Nutrition and cancer: the current epidemiological evidence. Br J Nutr. 2006 Aug;96 Suppl 1:S42-5.
25. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007 Apr;19(2):150-8.
26. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol. 2001 Apr;3(4):433-8.
27. Jass JR, Barker M, Fraser L, Walsh MD, Whitehall VL, Gabrielli B, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol. 2003 Jan;56(1):69-73.
28. Senda T, Iizuka-Kogo A, Onouchi T, Shimomura A. Adenomatous polyposis coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol Morphol. 2007 Jun;40(2):68-81.
29. Kwong LN, Dove WF. APC and its modifiers in colon cancer. Adv Exp Med Biol. 2009;656:85-106.
30. Shitashige M, Hirohashi S, Yamada T. Wnt signaling inside the nucleus. Cancer Sci. 2008 Apr;99(4):631-7.
31. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17.
32. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008 Jan 21;14(3):378-89.
33. Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008 May 7;14(17):2662-9.
34. Burstein E, Fearon ER. Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest. 2008 Feb;118(2):464-7.
35. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 2008 Jul;118(7):2516-25.

36. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000 Sep;157(3):737-45.

37. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19-26;420(6917):860-7.

38. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000 Jul 1;60(13):3333-7.

39. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res. 2001;27(1):17-26.

40. Nakashima K, Virgona N, Miyazawa M, Watanabe T, Yano T. The tocotrienol-rich fraction from rice bran enhances cisplatin-induced cytotoxicity in human mesothelioma H28 cells. Phytother Res. Sep;24(9):1317-21.

41. Norazalina S, Norhaizan ME, Hairuszah I, Norashareena MS. Anticarcinogenic efficacy of phytic acid extracted from rice bran on azoxymethane-induced colon carcinogenesis in rats. Exp Toxicol Pathol. May;62(3):259-68.

42. Aggarwal BB, Sundaram C, Prasad S, Kannappan R. Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases. Biochem Pharmacol. Dec 1;80(11):1613-31.

43. Shamsuddin AM. Inositol phosphates have novel anticancer function. J Nutr. 1995 Mar;125(3 Suppl):725S-32S.

44. Sylvester PW, Kaddoumi A, Nazzal S, El Sayed KA. The value of tocotrienols in the prevention and treatment of cancer. J Am Coll Nutr. Jun; 29(3 Suppl):324S-33S.

45. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. J Nutr. 2003 Nov; 133(11 Suppl 1):3778S-84S.

46. Vucenik I, Tomazic VJ, Fabian D, Shamsuddin AM. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett. 1992 Jul 31;65(1):9-13.

47. Liu QL, Xu XH, Ren XL, Fu HW, Wu DX, Shu QY. Generation and characterization of low phytic acid germplasm in rice (*Oryza sativa* L.). Theor Appl Genet. 2007 Mar;114(5):803-14.

48. Nesaretnam K. Multitargeted therapy of cancer by tocotrienols. Cancer Lett. 2008 Oct 8;269(2):388-95.

49. Kawabata K, Tanaka T, Murakami T, Okada T, Murai H, Yamamoto T, et al. Dietary prevention of azoxymethane-induced colon carcinogenesis with rice-germ in F344 rats. Carcinogenesis. 1999 Nov;20(11):2109-15.

50. Tomita H, Kuno T, Yamada Y, Oyama T, Asano N, Miyazaki Y, et al. Preventive effect of fermented brown rice and rice bran on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Oncol Rep. 2008 Jan;19(1):11-5.

51. Kuno T, Hirose Y, Yamada Y, Hata K, Qiang SH, Asano N, et al. Chemoprevention of mouse urinary bladder carcinogenesis by fermented brown rice and rice bran. Oncol Rep. 2006 Mar;15(3):533-8.

52. Kuno T, Hirose Y, Hata K, Kato K, Qiang SH, Kitaori N, et al. Preventive effect of fermented brown rice and rice bran on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats. Int J Oncol. 2004 Dec;25(6): 1809-15.

53. Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol. 2009;57:31-89.

54. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila). 2009 Jun;2(6):525-30.

55. Shimkin MB, Stoner GD. Lung tumors in mice: application to carcinogenesis bioassay. Adv Cancer Res. 1975;21:1-58.

56. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction--executive summary. Tob Control. 2001 Jun;10(2):189-95.

57. Witschi H. A/J mouse as a model for lung tumorigenesis caused by tobacco smoke: strengths and weaknesses. Exp Lung Res. 2005 Jan-Feb;31(1):3-18.

58. Hecht SS. Carcinogenicity studies of inhaled cigarette smoke in laboratory animals: old and new. Carcinogenesis. 2005 Sep;26(9):1488-92.

59. Malkinson AM. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res. 1992 May 1; 52(9 Suppl):2670s-6s.

60. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2(3):541-6.

61. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol. 2007 Nov 14;13(42):5581-93.

62. Desreumaux P, Colombel JF. [Intestinal flora and Crohn's disease]. Ann Pharm Fr. 2003 Jul;61(4):276-81.

63. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl. 2001(234):29-40.

64. Lugea A, Salas A, Casalot J, Guarner F, Malagelada JR. Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins. Gut. 2000 Apr;46(4):515-21.

65. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 1997 Dec;92(12 Suppl):5S-11S.

66. Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep. 2007 Dec;9(6):497-507.

67. Westbrook AM, Szakmary A, Schiestl RH. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res. Jul-Sep;705(1):40-59.

68. Clarke AR. Wnt signalling in the mouse intestine. Oncogene. 2006 Dec 4;25(57):7512-21.

69. McCart AE, Vickaryous NK, Silver A. Apc mice: models, modifiers and mutants. Pathol Res Pract. 2008;204(7):479-90.

70. Yamada Y, Mori H. Multistep carcinogenesis of the colon in Apc(Min/+) mouse. Cancer Sci. 2007 Jan;98(1):6-10.

71. Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007 Sep;28(9):1450-9.

72. Cooper HS, Everley L, Chang WC, Pfeiffer G, Lee B, Murthy S, et al. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology. 2001 Dec;121(6):1407-16.

73. Tanaka T, Kohno H, Suzuki R, Hata K, Sugie S, Niho N, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer. 2006 Jan 1;118(1):25-34.

74. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007 January 1, 2007;57(1):43-66.

75. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin. 2004 May-Jun;54(3):150-80.

76. Boyd JA, Barrett JC. Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther. 1990;46(3):469-86.

77. Armitage P. Multistage models of carcinogenesis. Environ Health Perspect. 1985 Nov;63:195-201.

78. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006 Jun;17 Suppl 7:vii97-102.

79. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res. 2010 Jun;27(6):1049-53.

80. Zheng HC, Takano Y. NNK-Induced Lung Tumors: A Review of Animal Model. J Oncol. 2011;2011:635379.

81. Afshar CE, Katz AK, Carrell HL, Amin S, Desai D, Glusker JP. Three-dimensional structure of anti-5,6-dimethylchrysene-1, 2-dihydrodiol-3,4-epoxide: a diol epoxide with a bay region methyl group. Carcinogenesis. 1999 Aug;20(8):1549-53.

82. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):890-4.

83. D'Agostino J, Zhang X, Wu H, Ling G, Wang S, Zhang QY, et al. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab Dispos. 2008 Nov;36(11):2316-23.

84. Fujieda M, Yamazaki H, Saito T, Kiyotani K, Gyamfi MA, Sakurai M, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis. 2004 Dec;25(12):2451-8.

85. Wang SL, He XY, Shen J, Wang JS, Hong JY. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant. Toxicol Sci. 2006 Nov;94(1):38-45.

86. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol. 1999 Jun 15;57(12):1407-13.

87. Brown PJ, Bedard LL, Reid KR, Petsikas D, Massey TE. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes. Drug Metab Dispos. 2007 Nov;35(11):2086-94.

88. Honkakoski P, Negishi M. The structure, function, and regulation of cytochrome P450 2A enzymes. Drug Metab Rev. 1997 Nov;29(4):977-96.

89. Lindberg R, Burkhart B, Ichikawa T, Negishi M. The structure and characterization of type I P-450(15) alpha gene as major steroid 15 alpha-hydroxylase and its comparison with type II P-450(15) alpha gene. J Biol Chem. 1989 Apr 15;264(11):6465-71.

90. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000 Sep 15;60(18):5074-9.

91. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis. 1988 Jun;9(6):875-84.

92. Ziegel R, Shallop A, Jones R, Tretyakova N. K-ras gene sequence effects on the formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-DNA adducts. Chem Res Toxicol. 2003 Apr;16(4):541-50.

93. Devereux TR, Anderson MW, Belinsky SA. Role of ras protooncogene activation in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse. Carcinogenesis. 1991 Feb;12(2):299-303.

94. Kawano R, Takeshima Y, Inai K. Effects of K-ras gene mutations in the development of lung lesions induced by 4-(N-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone in A/J mice. Jpn J Cancer Res. 1996 Jan;87(1):44-50.

95. Oreffo VI, Lin HW, Padmanabhan R, Witschi H. K-ras and p53 point mutations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumors. Carcinogenesis. 1993 Mar;14(3):451-5.

96. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005 Apr 15; 14 Spec No 1:R65-76.

97. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004 May 27;429(6990):457-63.

98. Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY, Tang YA, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. 2010 Feb;120(2):521-32.

99. Witschi H. The complexities of an apparently simple lung tumor model: The A/J mouse. Exp Toxicol Pathol. 2005 Jul;57 Suppl 1:171-81.

100. Imaida K, Yokohira M, Hashimoto N, Kuno T. Risk analysis of environmental chemicals on lung carcinogenesis. Asian Pac J Cancer Prev. 2010;11(1):9-12.

101. Chung FL. The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Proc Soc Exp Biol Med. 1999 Apr;220(4):244-8.

102. Brzezianska E, Pastuszak-Lewandoska D. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Front Biosci. 2011;16:422-39.

103. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010 Apr;1802(4):396-405.

104. Bhola NE, Grandis JR. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci. 2008;13:1857-65.

105. Wang D, Hu L, Zhang G, Zhang L, Chen C. G protein-coupled receptor 30 in tumor development. Endocrine. 2010 Aug;38(1):29-37.

106. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007 Apr;7(4):295-308.

107. Calcagno SR, Li S, Colon M, Kreinest PA, Thompson EA, Fields AP, et al. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer. 2008 Jun 1;122(11):2462-70.

108. Smit MJ, Verzijl D, Iyengar R. Identity of adenylyl cyclase isoform determines the rate of cell cycle progression in NIH 3T3 cells. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15084-9.

109. Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F. Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney Int. 1999 Oct;56(4):1258-61.

110. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994 Dec 16;266(5192):1821-8.

111. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989 Nov 3;246(4930):629-34.

112. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 1996 Feb;10(2):238-47.

113. Shackelford RE, Kaufmann WK, Paules RS. Cell cycle control, checkpoint mechanisms, and genotoxic stress. Environ Health Perspect. 1999 Feb; 107 Suppl 1:5-24.

114. Planas-Silva MD, Weinberg RA. The restriction point and control of cell proliferation. Curr Opin Cell Biol. 1997 Dec;9(6):768-72.

115. Zetterberg A, Larsson O, Wiman KG. What is the restriction point? Curr Opin Cell Biol. 1995 Dec;7(6):835-42.

116. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle. 2002 Mar-Apr;1(2):103-10.

117. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974 Apr;71(4):1286-90.

118. Chan GK, Yen TJ. The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit. Prog Cell Cycle Res. 2003;5:431-9.

119. Musacchio A. Spindle assembly checkpoint: the third decade. Philos Trans R Soc Lond B Biol Sci. 2011 Dec 27;366(1584):3595-604.

120. de Medina-Redondo M, Meraldi P. The spindle assembly checkpoint: clock or domino? Results Probl Cell Differ. 2011;53:75-91.

121. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol. 2007 May;8(5):379-93.

122. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol. 2012 Jan;226(2):352-64.

123. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261-91.

124. Cross FR, Buchler NE, Skotheim JM. Evolution of networks and sequences in eukaryotic cell cycle control. Philos Trans R Soc Lond B Biol Sci. 2011 Dec 27;366(1584):3532-44.

125. Garrett MD. Cell cycle control and cancer. Current Science. 2001;81(5).

126. Taya Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci. 1997 Jan;22(1):14-7.

127. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000 Oct 1;14(19):2393-409.

128. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000 May;42(5 Pt 1):705-22; quiz 23-6.

129. Roberts CW, Orkin SH. The SWI/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004 Feb;4(2):133-42.

130. Zhang HS, Dean DC. Rb-mediated chromatin structure regulation and transcriptional repression. Oncogene. 2001 May 28;20(24):3134-8.

131. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 1999 Sep 17;98(6):859-69.

132. Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 2000 Sep 15;14(18):2298-313.

133. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 1997 Jun 1;11(11):1464-78.

134. Kariya K, Koyama S, Nakashima S, Oshiro T, Morinaka K, Kikuchi A. Regulation of complex formation of POB1/epsin/adaptor protein complex 2 by mitotic phosphorylation. J Biol Chem. 2000 Jun 16;275(24):18399-406.

135. Heix J, Vente A, Voit R, Budde A, Michaelidis TM, Grummt I. Mitotic silencing of human rRNA synthesis: inactivation of the promoter selectivity factor SL1 by cdc2/cyclin B-mediated phosphorylation. EMBO J. 1998 Dec 15;17(24):7373-81.

136. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, Nigg EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995 Dec 29;83(7):1159-69.

137. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 1999 May 14;97(4):431-4.

138. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998 Dec 15;17(24):7151-60.

139. Harper JW, Elledge SJ. The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev. 1998 Feb 1;12(3):285-9.

140. Norbury C, Blow J, Nurse P. Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J. 1991 Nov;10(11):3321-9.

141. Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992 Sep 25;257(5078):1955-7.

142. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol. 1997 Feb;17(2):571-83.

143. Draetta G, Eckstein J. Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta. 1997 Apr 18;1332(2):M53-63.

144. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993 Dec 16;366(6456):704-7.

145. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149-63.

146. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1;11(7):847-62.

147. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999 Mar 15;18(6): 1571-83.

148. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000 Jul 15;60(14):3689-95.

149. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995 Oct 6;270(40):23589-97.

150. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol. 1999 Feb;19(2):1346-58.

151. Stambolic V, Mak TW, Woodgett JR. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene. 1999 Nov 1;18(45): 6094-103.

152. Marshall CJ. The ras oncogenes. J Cell Sci Suppl. 1988;10:157-69.

153. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67-108.

154. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000 Apr;183(1):10-7.

155. Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000 Jul 7;102(1):55-66.

156. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, et al. Rapid destruction of human Cdc25A in response to DNA damage. Science. 2000 May 26;288(5470):1425-9.

157. Carson DA, Lois A. Cancer progression and p53. Lancet. 1995 Oct 14;346(8981):1009-11.

158. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris). 2000 Apr;48(3):190-202.

159. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene. 1999 Dec 13;18(53):7637-43.

160. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 2000 Mar 10;287(5459):1824-7.

161. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999 Dec 24;286(5449):2528-31.

162. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94.

163. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene. 1999 Nov 1;18(45):6135-44.

164. Rowley R, Phillips EN, Schroeder AL. The effects of ionizing radiation on DNA synthesis in eukaryotic cells. Int J Radiat Biol. 1999 Mar;75(3):267-83.

165. Rhind N, Russell P. Checkpoints: it takes more than time to heal some wounds. Curr Biol. 2000 Dec 14-28;10(24):R908-11.

166. Petrini JH. The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol. 2000 Jun;12(3):293-6.

167. Paull TT, Gellert M. Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev. 1999 May 15;13(10):1276-88.

168. Wang JY. Cancer. New link in a web of human genes. Nature. 2000 May 25;405(6785):404-5.

169. Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 1997 Aug;17(8):4877-82.

170. Guo CY, D'Anna JA, Li R, Larner JM. The radiation-induced S-phase checkpoint is independent of CDKN1A. Radiat Res. 1999 Feb;151(2):125-32.

171. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene. 1999 Dec 20;18(55):7883-99.

172. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998 Nov 20;282(5393):1497-501.

173. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature. 1999 Oct 7;401(6753):616-20.

174. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001 Mar;3(3):245-52.

175. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, et al. Cell death: apoptosis versus necrosis (review). Int J Oncol. 2002 Jul;21(1):165-70.

176. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ. 2005 Nov;12 Suppl 2:1463-7.

177. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009 Jan;16(1):3-11.

178. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer. 2004 Aug;4(8):592-603.

179. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist. 2006 Apr;11(4):342-57.

180. Denault JB, Boatright K. Apoptosis in Biochemistry and Structural Biology. 3-8 February 2004, Keystone, CO, USA. IDrugs. 2004 Apr;7(4):315-7.

181. Hengartner MO. The biochemistry of apoptosis. Nature. 2000 Oct 12;407(6805):770-6.

182. Schwartzman RA, Cidlowski JA. Apoptosis: the biochemistry and molecular biology of programmed cell death. Endocr Rev. 1993 Apr;14(2):133-51.

183. Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol. 1990 Sep;68(9):1071-4.

184. Prindull G. Apoptosis in the embryo and tumorigenesis. Eur J Cancer. 1995;31A(1):116-23.

185. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacology & Therapeutics. 2001;92(1):57-70.

186. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.

187. MacFarlane M, Williams AC. Apoptosis and disease: a life or death decision. EMBO Rep. 2004 Jul;5(7):674-8.

188. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972 Aug;26(4):239-57.

189. Zamzami N, Kroemer G. Condensed matter in cell death. Nature. 1999 Sep 9;401(6749):127-8.

190. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997 Aug 15;326 (Pt 1):1-16.

191. Rai NK, Tripathi K, Sharma D, Shukla VK. Apoptosis: a basic physiologic process in wound healing. Int J Low Extrem Wounds. 2005 Sep;4(3):138-44.

192. Nemes Z, Jr., Friis RR, Aeschlimann D, Saurer S, Paulsson M, Fesus L. Expression and activation of tissue transglutaminase in apoptotic cells of involuting rodent mammary tissue. Eur J Cell Biol. 1996 Jun;70(2):125-33.

193. Bortner CD, Oldenburg NB, Cidlowski JA. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 1995 Jan;5(1):21-6.

194. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem. 1997 Oct 17;272(42):26159-65.

195. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002 Apr;2(4):277-88.

196. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res. 2006 Apr 15;66(8):4309-18.

197. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med. 2000 Oct 16;192(8):21-6.

198. Martinvalet D, Zhu P, Lieberman J. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005 Mar;22(3):355-70.

199. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002 Jun;2(6):420-30.

200. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998 Aug 28;281(5381):1305-8.

201. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995 May 19;81(4): 495-504.

202. Wajant H. The Fas signaling pathway: more than a paradigm. Science. 2002 May 31;296(5573):1635-6.

203. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 1995 Nov 15;14(22):5579-88.

204. Donepudi M, Mac Sweeney A, Briand C, Grutter MG. Insights into the regulatory mechanism for caspase-8 activation. Mol Cell. 2003 Feb;11(2): 543-9.

205. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 1998 Oct 15;161(8):3936-42.

206. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999 Jan 15;274(3):1541-8.

207. Hitoshi Y, Lorens J, Kitada SI, Fisher J, LaBarge M, Ring HZ, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998 Apr;8(4):461-71.

208. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004 Jan 23;116(2):205-19.

209. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006 Aug 7;25(34):4798-811.

210. Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther. Jul;10(7):1125-36.

211. Sodhi RK, Singh N, Jaggi AS. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Vascul Pharmacol. Sep-Oct;53(3-4):77-87.

212. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003 Oct 15;17(20):2481-95.

213. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005 Jul;54(7):1024-33.

214. Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 2001 Mar 9;276(10):7320-6.

215. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature. 1998 Jan 1;391(6662):96-9.

216. Wolf BB, Schuler M, Echeverri F, Green DR. Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J Biol Chem. 1999 Oct 22;274(43):30651-6.

217. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science. 1997 Oct 10;278(5336):294-8.

218. Ferraro-Peyret C, Quemeneur L, Flacher M, Revillard JP, Genestier L. Caspase-independent phosphatidylserine exposure during apoptosis of primary T lymphocytes. J Immunol. 2002 Nov 1;169(9):4805-10.

219. Mandal D, Mazumder A, Das P, Kundu M, Basu J. Fas-, caspase 8-, and caspase 3-dependent signaling regulates the activity of the aminophospholipid translocase and phosphatidylserine externalization in human erythrocytes. J Biol Chem. 2005 Nov 25;280(47):39460-7.

220. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem. 2001 Jan 12;276(2):1071-7.

221. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998;60:601-17.

222. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994 Apr 15;73(8):2013-26.

223. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994 Jun;9(6):1799-805.

224. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988 Sep 29;335(6189):440-2.

225. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001 Apr;2(4):293-9.

226. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994 Mar 25;263(5154):1759-62.

227. Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int J Oncol. 2001 Jan;18(1):33-9.

228. Koyama S, Koike N, Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma. J Cancer Res Clin Oncol. 2001 Jan;127(1):20-6.

229. Wang XW, Harris CC. p53 tumor-suppressor gene: clues to molecular carcinogenesis. J Cell Physiol. 1997 Nov;173(2):247-55.

230. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology. 2002 Dec 27;181-182:475-81.

231. Varley JM, Evans DG, Birch JM. Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer. 1997;76(1):1-14.

232. Gu J, Kawai H, Wiederschain D, Yuan ZM. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res. 2001 Feb 15;61(4):1741-6.

233. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst). 2004 Aug-Sep; 3(8-9):889-900.

234. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002 Jul;2(7):489-501.

235. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007 Mar;127(3):514-25.

236. Feghali CA, Wright TM. Cytokines in acute and chronic inflammation. Front Biosci. 1997 Jan 1;2:d12-26.

237. Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy. 2011 Oct;3(10):1265-74.

238. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006;13:118-37.

239. Potack J, Itzkowitz SH. Colorectal cancer in inflammatory bowel disease. Gut Liver. 2008 Sep;2(2):61-73.

240. Wong NA, Harrison DJ. Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology. 2001 Sep;39(3):221-34.

241. Umetani N, Sasaki S, Watanabe T, Shinozaki M, Matsuda K, Ishigami H, et al. Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. Jpn J Cancer Res. 1999 Oct;90(10):1081-7.

242. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 2004 Jul;3(5):394-400.

243. You J, Nguyen AV, Albers CG, Lin F, Holcombe RF. Wnt pathway-related gene expression in inflammatory bowel disease. Dig Dis Sci. 2008 Apr;53(4):1013-9.

244. Goel GA, Kandiel A, Achkar JP, Lashner B. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol. 2011 Apr;106(4):719-30.

245. Du Q, Park KS, Guo Z, He P, Nagashima M, Shao L, et al. Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. Cancer Res. 2006 Jul 15;66(14):7024-31.

246. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998 Sep 4;281(5382):1509-12.

247. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AM. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 1999 Apr 1;59(7):1572-7.

248. Klingensmith J, Nusse R, Perrimon N. The Drosophila segment polarity gene dishevelled encodes a novel protein required for response to the wingless signal. Genes Dev. 1994 Jan;8(1):118-30.

249. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal. 2008 Apr;20(4):581-9.

250. Brown JD, Moon RT. Wnt signaling: why is everything so negative? Curr Opin Cell Biol. 1998 Apr;10(2):182-7.

251. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci. 2002 Nov 1;115(Pt 21):3977-8.

252. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.

253. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem. 1999 Jun 4;274(23):16180-7.

254. Zorn AM. Wnt signalling: antagonistic Dickkopfs. Curr Biol. 2001 Aug 7;11(15):R592-5.

255. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA. New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle. 2009 Aug 15;8(16):2549-56.

256. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst. 1998 Oct 21;90(20):1514-28.

257. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003 Oct;3(10):768-80.

258. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2193-203.

259. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol. 2007 Aug 15;74(4):533-44.

260. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999 Apr 16;287(5):821-8.

261. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000 Oct 15;60(8):1051-9.

262. Nakanishi M, Shimada M, Niida H. Genetic instability in cancer cells by impaired cell cycle checkpoints. Cancer Sci. 2006 Oct;97(10):984-9.

263. Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, Zhou Y, et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol. 2008 Jan;128(1): 175-87.

264. Lee YM, Lim do Y, Cho HJ, Seon MR, Kim JK, Lee BY, et al. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity. Cancer Lett. 2009 Nov 28;285(2):166-73.

265. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006 Feb;5(2):296-308.

266. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst. 1997 Dec 17;89(24): 1881-6.

267. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis. 2007 Feb;28(2):233-9.

268. Long NK, Makita H, Yamashita T, Toida M, Kato K, Hatakeyama D, et al. Chemopreventive effect of fermented brown rice and rice bran on 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats. Oncol Rep. 2007 Apr;17(4):879-85.

269. Katayama M, Sugie S, Yoshimi N, Yamada Y, Sakata K, Qiao Z, et al. Preventive effect of fermented brown rice and rice bran on diethylnitrosoamine and phenobarbital-induced hepatocarcinogenesis in male F344 rats. Oncol Rep. 2003 Jul-Aug;10(4):875-80.

270. Katayama M, Yoshimi N, Yamada Y, Sakata K, Kuno T, Yoshida K, et al. Preventive effect of fermented brown rice and rice bran against colon carcinogenesis in male F344 rats. Oncol Rep. 2002 Jul-Aug;9(4):817-22.

271. Stone WL, Krishnan K, Campbell SE, Qui M, Whaley SG, Yang H. Tocopherols and the treatment of colon cancer. Ann N Y Acad Sci. 2004 Dec;1031:223-33.

272. Theriault A, Chao JT, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clin Biochem. 1999 Jul;32(5):309-19.

273. Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit Rev Clin Lab Sci. 2008;45(5):417-50.

274. Campbell S, Stone W, Whaley S, Krishnan K. Development of gamma (gamma)-tocopherol as a colorectal cancer chemopreventive agent. Crit Rev Oncol Hematol. 2003 Sep;47(3):249-59.

275. Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol. 2003 Mar;88(3):434-9.

276. Halliwell B, Rafter J, Jenner A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr. 2005 Jan;81(1 Suppl):268S-76S.

277. Miyazawa T, Shibata A, Sookwong P, Kawakami Y, Eitsuka T, Asai A, et al. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol). J Nutr Biochem. 2009 Feb;20(2):79-86.

278. Singh U, Devaraj S. Vitamin E: inflammation and atherosclerosis. Vitam Horm. 2007;76:519-49.

279. Sun W, Xu W, Liu H, Liu J, Wang Q, Zhou J, et al. gamma-Tocotrienol induces mitochondria-mediated apoptosis in human gastric adenocarcinoma SGC-7901 cells. J Nutr Biochem. 2009 Apr;20(4):276-84.

280. Wada S. Chemoprevention of tocotrienols: the mechanism of antiproliferative effects. Forum Nutr. 2009;61:204-16.

281. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 2005 Nov 18;229(2):181-91.

282. Graf E, Eaton JW. Antioxidant functions of phytic acid. Free Radic Biol Med. 1990;8(1):61-9.

283. Szwergold BS, Graham RA, Brown TR. Observation of inositol pentakis- and hexakis-phosphates in mammalian tissues by 31P NMR. Biochem Biophys Res Commun. 1987 Dec 31;149(3):874-81.

284. Inositol hexaphosphate. Monograph. Altern Med Rev. 2002 Jun;7(3):244-8.

285. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neoplastic agent: a systematic review. Complement Ther Med. 2002 Dec;10(4):229-34.

286. Guido M, Fagundes DJ, Ynouye CM, Pontes ER, Takita LC, Siufi do Amaral EG, et al. Apoptotic effects of inositol hexaphosphate on biomarker Itpr3 in induced colon rat carcinogenesis. Acta Cir Bras. 2008 Mar-Apr;23(2):157-64.

287. Johnson M, Tucci M, Benghuzzi H, Cason Z, Hughes J. The effects of inositol hexaphosphate on the inflammatory response in transformed RAW 264.7 macrophages. Biomed Sci Instrum. 2000;36:21-6.

288. Somasundar P, Riggs DR, Jackson BJ, Cunningham C, Vona-Davis L, McFadden DW. Inositol hexaphosphate (IP6): a novel treatment for pancreatic cancer. J Surg Res. 2005 Jun 15;126(2):199-203.

289. Wattenberg LW. Chemoprevention of pulmonary carcinogenesis by myo-inositol. Anticancer Res. 1999 Sep-Oct;19(5A):3659-61.

290. Witschi H, Espiritu I, Uyeminami D. Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis. 1999 Jul;20(7):1375-8.

291. Wolf DC, Whiteley HE, Everitt JI. Preneoplastic and neoplastic lesions of rat hereditary renal cell tumors express markers of proximal and distal nephron. Vet Pathol. 1995 Jul;32(4):379-86.

292. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000 Oct;25(2):169-93.

293. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996 Oct;6(10):986-94.

294. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol. 2003 Oct 13;3:18.

295. Britz SJ, Prasad PV, Moreau RA, Allen LH, Jr., Kremer DF, Boote KJ. Influence of growth temperature on the amounts of tocopherols, tocotrienols, and gamma-oryzanol in brown rice. J Agric Food Chem. 2007 Sep 5;55(18):7559-65.

296. Jayat C, Ratinaud MH. Cell cycle analysis by flow cytometry: principles and applications. Biol Cell. 1993;78(1-2):15-25.

297. Nunez R. DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol. 2001 Jul;3(3):67-70.

298. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994 Sep 1;84(5): 1415-20.

299. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995 Jul 17;184(1):39-51.

300. Zhang G, Gurtu V, Kain SR, Yan G. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques. 1997 Sep;23(3):525-31.

301. Hacker G. The morphology of apoptosis. Cell Tissue Res. 2000 Jul;301(1):5-17.

302. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol. 2002 Aug;31(4): 214-23.

303. Ziegler U, Groscurth P. Morphological features of cell death. News Physiol Sci. 2004 Jun;19:124-8.

304. Malick LE, Wilson RB. Modified thiocarbohydrazide procedure for scanning electron microscopy: routine use for normal, pathological, or experimental tissues. Stain Technol. 1975 Jul;50(4):265-9.

305. Seligman AM, Wasserkrug HL, Hanker JS. A new staining method (OTO) for enhancing contrast of lipid--containing membranes and droplets in osmium tetroxide--fixed tissue with osmiophilic thiocarbohydrazide(TCH). J Cell Biol. 1966 Aug;30(2):424-32.

306. Klaude M, Eriksson S, Nygren J, Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat Res. 1996 Jun 12;363(2):89-96.

307. Olive PL, Wlodek D, Banath JP. DNA double-strand breaks measured in individual cells subjected to gel electrophoresis. Cancer Res. 1991 Sep 1;51(17):4671-6.

308. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988 Mar;175(1):184-91.

309. Brown NS, Bicknell R. Cell migration and the boyden chamber. Methods Mol Med. 2001;58:47-54.

310. Chen HC. Boyden chamber assay. Methods Mol Biol. 2005;294:15-22.

311. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem. 2006 May 19;281(20):14446-56.

312. Antonicelli F, Brown D, Parmentier M, Drost EM, Hirani N, Rahman I, et al. Regulation of LPS-mediated inflammation in vivo and in vitro by the thiol antioxidant Nacystelyn. Am J Physiol Lung Cell Mol Physiol. 2004 Jun;286(6):L1319-27.

313. Bhattacharyya S, Dudeja PK, Tobacman JK. Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G784-90.

314. Gungor N, Pennings JL, Knaapen AM, Chiu RK, Peluso M, Godschalk RW, et al. Transcriptional profiling of the acute pulmonary inflammatory response induced by LPS: role of neutrophils. Respir Res. 2010;11:24.

315. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001 Jan;107(1):7-11.

316. Gookin JL, Chiang S, Allen J, Armstrong MU, Stauffer SH, Finnegan C, et al. NF-kappaB-mediated expression of iNOS promotes epithelial defense against infection by Cryptosporidium parvum in neonatal piglets. Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G164-74.

317. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol. 1999 Apr;19(4):2690-8.

318. Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol. 2007;595: 269-300.

319. Shu L, Cheung KL, Khor TO, Chen C, Kong AN. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev. 2010 Sep;29(3):483-502.

320. Seril DN, Liao J, Ho KL, Warsi A, Yang CS, Yang GY. Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci. 2002 Jun;47(6):1266-78.

321. Murakami A, Hayashi R, Tanaka T, Kwon KH, Ohigashi H, Safitri R. Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem Pharmacol. 2003 Oct 1;66(7):1253-61.

322. Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, et al. Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice. Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1262-7.

323. Campos FG, Logullo Waitzberg AG, Kiss DR, Waitzberg DL, Habr-Gama A, Gama-Rodrigues J. Diet and colorectal cancer: current evidence for etiology and prevention. Nutr Hosp. 2005 Jan-Feb;20(1):18-25.

324. Deshpande A, Dhadi SR, Hager EJ, Ramakrishna W. Anticancer Activity of Rice Callus Suspension Culture. Phytother Res. 2011 Dec 30.

325. Hui C, Bin Y, Xiaoping Y, Long Y, Chunye C, Mantian M, et al. Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo. Nutr Cancer. 2010;62(8):1128-36.

326. Mori H, Kawabata K, Matsunaga K, Ushida J, Fujii K, Hara A, et al. Chemopreventive effects of coffee bean and rice constituents on colorectal carcinogenesis. Biofactors. 2000;12(1-4):101-5.

327. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos. 2004 Jan;32(1):72-9.

328. Tulunay OE, Hecht SS, Carmella SG, Zhang Y, Lemmonds C, Murphy S, et al. Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1283-6.

329. Bacchi CE, Gown AM. Detection of cell proliferation in tissue sections. Braz J Med Biol Res. 1993 Jul;26(7):677-87.

330. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol. 2007 Fall;18(3):145-9.

331. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004 Jul;57(7):675-81.

332. Gatter KC, Dunnill MS, Gerdes J, Stein H, Mason DY. New approach to assessing lung tumours in man. J Clin Pathol. 1986 Jun;39(6):590-3.

333. Soomro IN, Whimster WF. Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol. 1990 Nov;162(3):217-22.

334. D'Ambrosio SM, Gibson-D'Ambrosio RE, Wani G, Casto B, Milo GE, Kelloff GJ, et al. Modulation of Ki67, p53 and RARbeta expression in normal, premalignant and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res. 2001 Sep-Oct;21(5):3229-35.

335. Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res. 2003 Oct 1;9(12):4324-31.

336. Esaki H, Kawakishi S, Morimitsu Y, Osawa T. New potent antioxidative o-dihydroxyisoflavones in fermented Japanese soybean products. Biosci Biotechnol Biochem. 1999 Sep;63(9):1637-9.

337. Hirota A, Taki S, Kawaii S, Yano M, Abe N. 1,1-Diphenyl-2-picrylhydrazyl radical-scavenging compounds from soybean miso and antiproliferative activity of isoflavones from soybean miso toward the cancer cell lines. Biosci Biotechnol Biochem. 2000 May;64(5):1038-40.

338. Chen YC, Inaba M, Abe N, Hirota A. Antimutagenic activity of 8-hydroxyisoflavones and 6-hydroxydaidzein from soybean miso. Biosci Biotechnol Biochem. 2003 Apr;67(4):903-6.

339. Ohta T, Nakatsugi S, Watanabe K, Kawamori T, Ishikawa F, Morotomi M, et al. Inhibitory effects of Bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones. Carcinogenesis. 2000 May;21(5):937-41.

340. Fukutake M, Takahashi M, Ishida K, Kawamura H, Sugimura T, Wakabayashi K. Quantification of genistein and genistin in soybeans and soybean products. Food Chem Toxicol. 1996 May;34(5):457-61.

341. Zhou JR, Yu L, Zhong Y, Blackburn GL. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr. 2003 Feb;133(2):516-21.

342. Hudson EA, Dinh PA, Kokubun T, Simmonds MS, Gescher A. Characterization of potentially chemopreventive phenols in extracts of brown rice that inhibit the growth of human breast and colon cancer cells. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1163-70.

343. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009;48(6):811-21.

344. Galati G, Teng S, Moridani MY, Chan TS, O'Brien PJ. Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metabol Drug Interact. 2000;17(1-4):311-49.

345. Khan N, Adhami VM, Mukhtar H. Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer. 2010 Mar;17(1): R39-52.

346. Sun SY, Hail N, Jr., Lotan R. Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst. 2004 May 5;96(9):662-72.

347. Brenner D, Mak TW. Mitochondrial cell death effectors. Curr Opin Cell Biol. 2009 Dec;21(6):871-7.

348. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med. 2010 Feb;31(1):93-112.

349. Wilankar C, Khan NM, Checker R, Sharma D, Patwardhan R, Gota V, et al. gamma-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma Through Activation of Both Intrinsic and Extrinsic Pathways. Curr Pharm Des. 2011 Jul 21;17(21):2176-89.

350. Inoue A, Takitani K, Koh M, Kawakami C, Kuno T, Tamai H. Induction of apoptosis by gamma-tocotrienol in human cancer cell lines and leukemic blasts from patients: dependency on Bid, cytochrome c, and caspase pathway. Nutr Cancer. 2011;63(5):763-70.

351. Das DK. Tocotrienols: Potential Drug Targets for Cardiovascular, Cancer and Neurologicl Diseases. Curr Pharm Des. 2011 Jul 21;17(21):2145-6.

352. Kannappan R, Gupta SC, Kim JH, Aggarwal BB. Tocotrienols fight cancer by targeting multiple cell signaling pathways. Genes Nutr. 2012 Apr 9;7(1): 43-52.

353. Sylvester PW, Kaddoumi A, Nazzal S, El Sayed KA. The value of tocotrienols in the prevention and treatment of cancer. J Am Coll Nutr. 2010 Jun;29 (3 Suppl):324S-33S.

354. Sylvester PW, Wali VB, Bachawal SV, Shirode AB, Ayoub NM, Akl MR. Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci. 2011;17:3183-95.

355. Sookwong P, Nakagawa K, Yamaguchi Y, Miyazawa T, Kato S, Kimura F. Tocotrienol distribution in foods: estimation of daily tocotrienol intake of Japanese population. J Agric Food Chem. 2010 Mar 24;58(6):3350-5.

356. Kataoka K, Ogasa S, Kuwahara T, Bando Y, Hagiwara M, Arimochi H, et al. Inhibitory effects of fermented brown rice on induction of acute colitis by dextran sulfate sodium in rats. Dig Dis Sci. 2008 Jun;53(6):1601-8.

357. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol. 1998 Aug;113(2):147-56.

358. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001 Aug 1;357(Pt 3):593-615.

359. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res. 2004 Nov 2;555(1-2):107-19.

360. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2442-7.

361. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7240-4.

362. Tetsuka T, Daphna-Iken D, Miller BW, Guan Z, Baier LD, Morrison AR. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. J Clin Invest. 1996 May 1;97(9):2051-6.

363. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem. 2000 May 5;275(18): 13427-30.

364. Cebrian D, Tapia A, Real A, Morcillo MA. Inositol hexaphosphate: a potential chelating agent for uranium. Radiat Prot Dosimetry. 2007;127(1-4):477-9.

365. Hurrell RF. Influence of vegetable protein sources on trace element and mineral bioavailability. J Nutr. 2003 Sep;133(9):2973S-7S.